Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$48.19 USD
-1.53 (-3.08%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $48.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$48.19 USD
-1.53 (-3.08%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $48.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Zacks News
Perrigo (PRGO) Down 8.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agios (AGIO) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Agios Pharmaceuticals' (AGIO) posts encouraging results for the second quarter. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.62% and 64.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.95% and 57.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for March 1st
by Zacks Equity Research
AGIO, ALIM, and BV have been added to the Zacks Rank #5 (Strong Sell) List on March 1, 2022
Agios (AGIO) Loss Wider Than Expected in Q4, Revenues Nil
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) posts wider-than-expected loss for the fourth quarter of 2021. It does not record any revenues in the quarter.
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics
by Zacks Equity Research
Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -5.85% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: SAGE, ATRA Down on Study Updates, AGIO Drug Approval & More
by Zacks Equity Research
Updates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week.
Agios (AGIO) Gets FDA Nod for Rare Anemia Drug Mitapivat
by Zacks Equity Research
Agios Pharmaceuticals' (AGIO) Pyrukynd (mitapivat) is the first disease-modifying therapy approved to treat PK deficiency, a rare, debilitating, blood disorder.
Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Agios Pharmaceuticals (AGIO) Down 24.6% Since Last Earnings Report?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agios (AGIO) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) posts narrower-than-expected loss for the third quarter of 2021. It does not record any revenues in the quarter.
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 8.07% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review
by Zacks Equity Research
Agios (AGIO) is seeking approval for its lead pipeline candidate, mitapivat, as a potential treatment for PK deficiency.
Agios' (AGIO) Q2 Loss Narrows, Pipeline Makes Solid Progress
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reports narrowed-than-expected loss for the second quarter of 2021. The company did not record any revenue following the oncology portfolio sale.
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 2.16% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios (AGIO) Files MAA in EU for Rare Genetic Disease Drug
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) files a MAA in Europe for its most advanced drug, mitapivat, to treat adults with pyruvate kinase deficiency.
Agios (AGIO) Files NDA to FDA for Rare Disease Drug Mitapivat
by Zacks Equity Research
Agios (AGIO) submits a new drug application to the FDA for its lead candidate, mitapivat, for treating adults with pyruvate kinase deficiency. Stock up.
Agios' (AGIO) Q1 Earnings Miss, Pipeline Makes Progress
by Zacks Equity Research
Agios (AGIO) incurs wider-than-expected loss in the first quarter of 2021. The company fails to record revenues due to the sale of its oncology portfolio including Tibsovo.
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -6.50% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Agios Pharmaceuticals (AGIO) Down 1.3% Since Last Earnings Report?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.